Professional Bio
Dr. Chen Yan received her Bachelor of Science degree in Biochemistry in 1983 and Master's degree in Human/Medical Genetics from the Fudan University in 1983. She received her Ph.D. degree in molecular pharmacology from the University of Washington (UW), Seattle in 1996 and performed her postdoctoral training in molecular cardiology, also at UW. She was recruited to the University of Rochester as a Research Assistant Professor in December 1998. She currently is a assistant professor.
Research Bio
General Research Interests: Regulation and function of cyclic nucleotide phosphodiesterases in the cardiovascular system. Second messenger cyclic nucleotides (cAMP and cGMP) regulate many signaling pathways in the cardiovascular system. For example, the vascular tone, smooth muscle cell growth, and cardiac muscle contractility are all regulated by cyclic nucleotide signaling. We are interested in phosphodiesterases (PDEs), the enzymes that break down cyclic nucleotides and thus control the amplitude, duration, and compartmentalization of cyclic nucleotide signaling in the cell. It has become increasingly clear that cyclic nucleotide degradation by PDEs is not a constitutive function of the cell, but rather a highly regulated one controlled by different mechanisms in different physiological and pathological circumstances.
PDE regulation and function is further complicated by the fact that there are more than 50 individual PDEs belonging to 11 different PDE families, yet our understanding of the physiological function of each PDE is far from complete. PDEs have been demonstrated to be good pharmacological targets for therapeutic agents due to the presence of multiple structurally different, tissue-specific, differentially regulated, and functionally distinct isozymes. Several drugs, such as Viagra, have been shown to have unique specific effects via selectively inhibit individual PDE isozymes. Our focus has been on determining the regulation and function of individual PDE isozymes in cardiovascular diseases such as hypertension, atherosclerosis, heart failure, and cardiovascular inflammatory diseases. Ongoing and future studies using in vitro and in vivo approaches will focus on the various roles of PDEs in cardiovascular physiology and pathology, which may provide new therapeutic information for tissue specific interventions in cardiovascular diseases.
2007 Oct 12
Surapisitchat J, Jeon KI, Yan C, Beavo JA. "Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3." Circulation research. 2007 Oct 12; 101(8):811-8. Epub 2007 Aug 17. |
2007 Aug
Lim JH, Stirling B, Derry J, Koga T, Jono H, Woo CH, Xu H, Bourne P, Ha UH, Ishinaga H, Xu H, Andalibi A, Feng XH, Zhu H, Huang Y, Zhang W, Weng X, Yan C, Yin Z, Briles DE, Davis RJ, Flavell RA, Li JD. "Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections." Immunity. 2007 Aug 0; 27(2):349-60. |
2007 Jul 6
Garin G, Abe J, Mohan A, Lu W, Yan C, Newby AC, Rhaman A, Berk BC. "Flow antagonizes TNF-alpha signaling in endothelial cells by inhibiting caspase-dependent PKC zeta processing." Circulation research. 2007 Jul 6; 101(1):97-105. Epub 2007 May 24. |
2007 Mar 2
Yan C, Ding B, Shishido T, Woo CH, Itoh S, Jeon KI, Liu W, Xu H, McClain C, Molina CA, Blaxall BC, Abe J. "Activation of extracellular signal-regulated kinase 5 reduces cardiac apoptosis and dysfunction via inhibition of a phosphodiesterase 3A/inducible cAMP early repressor feedback loop." Circulation research. 2007 Mar 2; 100(4):510-9. Epub 2007 Feb 01. |
2007 Mar 2
Yan C, Miller CL, Abe J. "Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart." Circulation research. 2007 Mar 2; 100(4):489-501. |
